TMEM237

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, TMEM237 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM237 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM237 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM237 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC and LSCC are the cancer types where TMEM237 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
HNSCDFSMedianII,III,IV0.7580.543.0224view →
LSCCDFSQuartileIII,IV0.8590.330.0262view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TMEM237–HNSC (DFS)

Kaplan–Meier survival curve for TMEM237 mass-spec protein-high vs -low samples in HNSC.

Open the HNSC breakdown →

Exploration